What is a DXd drug and how does this technology revolutionize cancer treatment?
•
3 min read
Over two decades, antibody-drug conjugates (ADCs) have transformed targeted cancer therapy, and the next-generation platform using a **DXd drug** as a payload is at the forefront of this innovation. This technology, pioneered by Daiichi Sankyo, is built around a potent topoisomerase I inhibitor, designed to precisely deliver chemotherapy to cancer cells while minimizing systemic harm.
